Is Willito actually on Ozempic? What GLP-1 weight loss really looks like

What did @chisme.w.jr actually say?

The creator opened with a confession, not a debate: "I am on ozambic. So what if I'm on ozambic?" That's the whole thesis. Someone was apparently speculating online about whether a person named Willito was using semaglutide, and this video is the response. The creator owns it, frames it as a personal choice, and essentially tells anyone skeptical to mind their business or try it themselves if they have the money.

There's no medical claim being made here. No dosage, no mechanism of action, no weight loss numbers. Just a person confirming use of a GLP-1 drug and defending their right to use it. That framing matters a lot when we evaluate what's actually being said versus what people might infer from watching it.

Does the science back this up?

There's nothing to fact-check scientifically here in the traditional sense, because no health claim was made. But the implicit suggestion, that Ozempic is something worth using if you can afford it, does have real evidence behind it.

Semaglutide, the active ingredient in Ozempic and Wegovy, is one of the most studied weight-loss interventions in recent history. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found that participants on 2.4mg weekly semaglutide lost an average of 14.9% of body weight over 68 weeks versus 2.4% on placebo. That's not a rounding error. The SELECT trial (Lincoff et al., 2023, NEJM) further showed a 20% reduction in major cardiovascular events in overweight adults without diabetes, which nobody was expecting when Ozempic first came to market as a diabetes drug.

So if someone is using it and it's working for them, the data isn't going to argue with that decision.

What did they get wrong (or right)?

Honestly? The creator didn't get much wrong, because they barely made a factual claim. What they got right is the cultural framing. Ozempic stigma is real, and it runs in both directions. People criticize celebrities and influencers for using it as a shortcut, while simultaneously the same drug is life-changing for people with type 2 diabetes and obesity-related cardiovascular risk.

The "if you got the money, do it too" line is worth pushing back on slightly. Access to semaglutide is genuinely inequitable. Brand-name Ozempic can run $900-$1,000 per month without insurance. Compounded versions exist in a gray market that the FDA has flagged for quality concerns, most recently in 2024 when the agency noted compounded semaglutide products are not FDA-approved and may contain different salt forms than the brand-name drug. So "just buy it" is easier said than done, and the creator glosses over a real access problem.

That's not a lie, but it's incomplete in a way that 914,000 views makes worth naming.

What should you actually know?

If you're watching this video and wondering whether GLP-1 drugs are right for you, here's what the research actually says, stripped of the drama.

• Semaglutide is FDA-approved for two separate indications: type 2 diabetes management (Ozempic, 0.5-2mg weekly) and chronic weight management in adults with obesity or overweight plus at least one weight-related condition (Wegovy, up to 2.4mg weekly). These are not the same drug in the same dose, and they're not interchangeable prescriptions.
• Side effects are real and common. The STEP trials reported nausea in roughly 44% of participants, vomiting in 24%, and diarrhea in 30%. Most were mild to moderate and tapered over time, but people deserve to know that before they romanticize the drug on TikTok.
• Weight often returns after stopping. A 2022 follow-up study (Wilding et al., Diabetes, Obesity and Metabolism) found participants regained two-thirds of their lost weight within one year of discontinuing semaglutide. It's a treatment, not a permanent fix.
• This drug requires a licensed prescriber. A telehealth visit is a legitimate pathway, but any platform offering it without a clinical evaluation is cutting corners that exist for safety reasons.

The creator's core point, that using Ozempic is a personal choice and nobody owes anyone an explanation for it, is defensible. What a 914K-view video can't do is replace a conversation with a clinician who actually knows your history.